In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
|Articles|August 11, 2016
FDA Grants Nivolumab Priority Review in Head and Neck Cancer
Author(s)Bobby Lazzara, MD
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in metastatic head and neck cancer.
Advertisement
In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara discusses the recent priority review of nivolumab for use in recurrent or metastatic head and neck cancer, based on results of the CheckMate-141 study.
The study found that nivolumab improved overall survival (7.5 vs 5.1 months) over investigator’s choice.
Advertisement
Related to this article
Interim phase 2 data show INBRX-106 plus pembrolizumab nearly doubled response rates and extended survival vs pembrolizumab alone in head and neck cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
NCCN Guidelines Strengthen MRD Testing Recommendations in Multiple Myeloma
5